Europe
Companies from across the globe provide updates on their business operations and pipeline development.
T cell redirecting cancer company Immatics Biotechnologies entered into a merger agreement with Arya Sciences Acquisition Corp. that will give the Germany-based company a listing on the Nasdaq exchange under the ticker symbol IMTX.
The consent decree, including the proposed purchasers, remains subject to further review and approval by the Commissioners of the FTC.
OncoOne currently has three drug candidates for four indications (colorectal, pancreatic, ovarian and lung cancers).
Haselmeier officially announces that it has received Master File Number MAF3202 from the Food and Drug Administration of the United States for its D-Flex product platform, a new generation of injection pen systems for subcutaneous self-administration.
There has been something of a furor over reports in the German newspaper Welt am Sonntag that claimed the Trump administration offered a “billion dollars” for exclusive rights to a coronavirus vaccine in development by German company CureVac, “but only for the USA.”
“We are pleased to see the sustained and meaningful survival benefit of Imfinzi for patients with small cell lung cancer after more than two years median follow up,” said Jose Baselga, Astra Zeneca’s executive vice president, Oncology R&D.
The two companies will focus on BioNTech’s BNT162, an mRNA-based vaccine candidate.
No more patients will be enrolled in the trials and current treatment “will cease” while they determine the risks and plans for the trials.
This St. Patrick’s Day, BioSpace takes a look at some of the most recent successes from four of Ireland’s most-noted companies.
PRESS RELEASES